Revance, which is one of the fastest-growing global aesthetics and skincare companies, announced that they’ve distributed over one million SkinPen treatments nationwide since January 2025.
The strong demand for SkinPen underscores rapid growth of microneedling and the market’s increasing demand for minimally invasive cosmetic treatments.
“Reaching one million SkinPen treatment kits sold since January 2025 is a powerful proof point – not only for SkinPen, but for the rapid growth of microneedling as an in-demand aesthetic treatment,” says Nadeem Moiz, Chief Executive Officer of Revance. “This momentum reflects our continued commitment to advancing the category through innovation, education, and clinically supported outcomes.”
To celebrate this milestone, SkinPen kicked off the $100 Reasons to Love SkinPen patient rebate program, where patients can save $100 on a series of three or more SkinPen treatments, running from February 1 to June 30, 2026.
“SkinPen continues to raise the bar for professional microneedling,” says Dr. Rishi Chopra, MD, MS, FAAD. “This accomplishment reinforces how quickly the category is evolving—and why clinically proven technology matters for both providers and patients.” Looking ahead, Revance will continue to invest in SkinPen to accelerate category growth and expand access for patients to experience its skin-changing results.
